中邮证券研报指出上海医药费用管控良好提质增效持续推进。公司包括进口总代、创新药服务、CSO、器械大健康在内的多项创新业务

智通财经
02 Jul
中邮证券研报指出上海医药费用管控良好提质增效持续推进。公司包括进口总代、创新药服务、CSO、器械大健康在内的多项创新业务保持良好增长。2025Q1公司进口总代业务实现销售收入86亿元同比增长9.0%。创新药业务实现销售收入125 亿元同比增长达到23.2%。在持续研发投入下多款产品获批及报产多个创新药研发以及中药二次开发项目取得积极进展。维持“买入”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10